Embecta Corp. (EMBC) Stock

About Embecta Corp.

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

Embecta Corp. is led by CEO Devdatt Kurdikar, employs 2,000 people, headquartered in US, publicly traded since 2022.

Embecta Corp. (EMBC) stock trades at $6.71 with a market capitalization of $380.19M. The stock is valued at a price-to-earnings (P/E) ratio of 4.15, a negative price-to-book of -0.59, reflecting negative shareholders' equity, price-to-sales of 0.34. Over the past 52 weeks the stock has ranged between $2.77 and $14.91, and currently trades 55.0% below its 52-week high. It pays a dividend yielding 0.65%.

On profitability, Embecta Corp. generates a return on equity (ROE) of -13.98% (not meaningful, as shareholders' equity is negative), return on capital employed of 29.93%, an operating margin of 30.46%, a net profit margin of 8.59%.

Official website: www.embecta.com

Embecta Corp. by the numbers, 2019–2025

Between 2019 and 2025 Embecta Corp. reported revenue of $1.1B rising to $1.1B, a change of -2.6% across 7 years. Compounded, revenue has grown -0.1% a year over five years, -1.5% over three, -3.8% over the last twelve months. Net profit fell to $95.0M.

Operating margin went from 45.3% in 2019 to 30.5% in 2025, a fall of 14.8 percentage points. The most recent net margin is 8.59%. On a trailing twelve-month basis to Jun '26, revenue is $1.0B and net profit $87.0M.

Borrowings stand at $1.4B, cash on hand is $215.0M, cash from operations was $192.0M in the latest year, positive in 7 of the last 7.

Return on equity has averaged 2.2% over five years, and was -14.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Embecta Corp. (EMBC) — frequently asked questions